What is Gamida Cell Ltd. (GMDA)?

Gamida Cell Ltd. (GMDA) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of GMDA?

The current price of GMDA is $0.03. Prices are updated in real time on Stocks360.

What is GMDA's price-to-earnings (PE) ratio?

GMDA's trailing twelve-month PE ratio is -0.08, based on current price and earnings per share data available on Stocks360.

What is GMDA's market capitalization?

GMDA's market capitalization is $4,337,295.00, placing it in the small-cap tier.

Gamida Cell Ltd. (GMDA)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.03

Market Cap

$4.34M

PE (TTM)

-0.08

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.03

Day Range

$0.03 – $0.04

52-wk Range

$0.03 – $0.04

Avg Volume

N/A

Volume

19.05M

Gamida Cell Ltd. (GMDA) is a publicly traded company in the Healthcare sector. Latest price: $0.03. Market cap $4.34M. Trailing PE -0.08. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 27, 2024

EPS $-0.04 vs est. $-0.13

Beat by $0.09

Proprietary Signals

Signal snapshot temporarily unavailable.

About Gamida Cell Ltd.

Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.08×
P/S (TTM)	2.43×
P/B	-1.65×
P/FCF (TTM)	-0.05×
EV / EBITDA	-0.76×
EV / Sales	22.83×
Earnings Yield	-1296.62%
Free Cash Flow Yield	-1849.10%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$40.73M
Revenue (TTM)	$1.78M
Net Income (TTM)	-$56.24M
Free Cash Flow (TTM)	-$72.61M
Net Debt	$36.39M
Working Capital	$29.34M
Gross Margin	-94.96%
Operating Margin	-4094.06%
Net Margin	-3531.17%
Return on Equity	1148.30%
Return on Invested Capital	-86.17%